Is Mangoceuticals, Inc. (MGRX) a Buy, Sell, or Hold?
NASDAQ : MGRX
Mangoceuticals, Inc. — News
$0.5571 USD
$0.26 (89.75%)
- Volume
- 512.12M
- Average Volume
- 10.59M
- Market Capitalization
- $5.65M
- P/E Ratio
- -0.32
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.75
- Year Low
- $0.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.03
- Current Ratio
- $0.29
| Source | Headline |
|---|---|
|
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Transaction positions Nuclea to fund the development and commercialization of its lead-cooled, factory-built microreactor as AI and data center growth drives a generational expansion in U.S. electricity demand Mississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announced that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals"). "This agreement gives Nuclea a faster path to the public markets at a defining moment for our industry. newsfilecorp.com - 2026-07-30 10:35:00 |
|
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Business Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitive business combination agreement (the “Agreement”) with Nuclea Energy Inc. (“Nuclea”), an advanced nuclear technology company founded in August 2023 and headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor. Nuclea is advancing its Morpheus nuclear reactor from the current design stage through an 18-month development roadmap toward regulatory and commercial readiness. globenewswire.com - 2026-07-30 07:00:00 |
